Study Details
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Clinicaltrials.gov ID
Astellas Study ID
OSI-774-107
EudraCT ID
2005-003883-46
Condition
Non Small Cell Lung Cancer
Phase
Phase 1
Age
18 Years - N/A N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Nov 2005 - Sep 2007
Masking
None (Open Label)
Enrollment number
57
A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (erlotinib) in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients with Stage IIIB/IV Non-small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Aberdeen Royal Infirmary
Aberdeen, United Kingdom, AB25 2ZN
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
University of Edinburgh,Division of Oncology,
Edinburgh, United Kingdom, EH4 2XU
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, United Kingdom, NE7 7DH
Department of Oncology
Sheffield, United Kingdom, S10 2SJ
Comprehensive Blood and Cancer Center
Bakersfield, United States, 93309
Wake Forest University Comprehensive Cancer Center
Winston-Salem, United States, 27157